UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report: ~~February~~March 1020, 2012

(Date of earliest event reported)

SCOLR Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-31982

91-1689591

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

~~19204~~13400 ~~North~~NE ~~Creek~~20th ~~Parkway~~Street, Suite ~~100~~44

~~Bothell~~Bellevue, ~~Washington~~WA ~~98011~~98005

(Address of principal executive offices and zip code)

(425) 368-1050

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

¨	Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SCOLR PHARMA, INC.

FORM 8-K

Item 1.01 Entry into a Material Definitive Agreement.

On ~~February~~March 1020, 2012, SCOLR Pharma, Inc. (the “Company”) ~~and~~executed ~~Brenner~~two ~~Construction~~Demand CoPromissory Notes, one in favor of Michael N. ~~d/b/~~Taglich, a ~~Brenner~~member ~~Properties~~of ~~entered~~the ~~into~~Company’s aBoard ~~lease agreement~~of Directors, ~~effective~~and asthe other in favor of ~~February~~Robert 7Taglich, ~~2012~~his brother (~~the~~each a “~~Lease”)~~Note,” ~~pursuant~~and totogether, ~~which~~ the ~~Company~~“Notes”). ~~will~~Each ~~lease~~note ~~approximately~~has ~~1,300~~an ~~square~~original ~~feet~~principal amount of ~~office~~$100,000 ~~space~~and bears interest at ~~13400~~a NErate ~~20th~~of ~~Street,~~eight ~~Bellevue,~~percent ~~Washington.~~(8%) ~~The~~per ~~term~~annum. ofThe ~~the~~Notes ~~lease~~are unsecured ~~is 13 months~~ and ~~shall~~are ~~commence~~payable on ~~March 1, 2012~~demand. The ~~Company~~ ~~intends~~applicable tointerest ~~relocate~~rate iton ~~headquarters~~the ~~from~~Notes ~~Bothell,~~increases ~~Washington,~~ to twelve percent (12%) upon the ~~new~~occurrence ~~space~~and during the ~~first~~continuance ~~quarter~~of an event of ~~2012.~~default, ~~The~~including ~~monthly~~the ~~base~~Company’s ~~rent~~failure ~~under~~to pay the ~~lease~~notes ~~is $1~~when due,~~793.00~~ ~~per~~subject ~~month~~to an applicable cure period.

ACopies ~~copy~~ of the ~~Lease~~Notes isare attached as Exhibit 10.1 and 10.2 to this current report and isare incorporated herein by reference. The foregoing description of the ~~Lease~~ Notes does not purport to be complete and is qualified in its entirety by reference to such ~~exhibit~~exhibits.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The disclosure contained under Item 1.01 above is incorporated into this item by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
10.1		~~Lease~~Demand Promissory Note, dated asMarch ~~of February 7~~20, ~~2012~~2011, ~~between~~issued by SCOLR Pharma, Inc. ~~and~~in ~~Brenner~~favor ~~Construction~~of CoMichael N. ~~d/b/a Brenner Properties~~Taglich.
10.2		Demand Promissory Note, dated March 20, 2011, issued by SCOLR Pharma, Inc. in favor of Robert Taglich

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCOLR Pharma, Inc.

(Registrant)

February 14, 2012

/s/ RICHARD M. LEVY

March 26, 2012

/s/ RICHARD M. LEVY

Richard M. Levy

Executive Vice President & Chief Financial Officer

Filing Compare · SCOLR Pharma, Inc.